Roivant Sciences Ltd.(ROIV)Company Profile & BusinessNASDAQ
Business, leadership and ownership
Company Profile
Business overview, scale, and footprint
Business Overview
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases.
In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
Insider Transactions
Open-market activity and option exercises
Insider Activity Summary
Insider trading activity for Roivant Sciences Ltd. (ROIV) between Jul 23, 2024 and Oct 1, 2026 consists of 164 total transactions. Among these, company executives and board members conducted 138 buys (totaling 135,286,579 shares) and 26 sells (totaling 3,310,965 shares). This activity resulted in a net change of 131,975,614 shares, reflecting net buying interest with an estimated net acquisitions value of $2.46B.
164 insider transactions found. Showing 10 of 164 transactions.
| Insider Name | Relation to Company | Shares Changed | Price | Transaction Date |
|---|---|---|---|---|
| Epperly Melissa B, | Director | -16,850 | $36.08 | Oct 1, 2026 |
| Epperly Melissa B, | Director | -900 | $36.57 | Oct 1, 2026 |
| Venker Eric | President & Immunovant CEO | -200,000 | $36.62 | Sep 30, 2026 |
| MANCHESTER KEITH S | Director | 5,054 | N/A | Sep 16, 2026 |
| FITZGERALD MEGHAN | Director | 5,054 | N/A | Sep 16, 2026 |
| MOMTAZEE JAMES C | Director | 5,054 | N/A | Sep 16, 2026 |
| EPPERLY MELISSA B | Director | 4,938 | $0.20 | Sep 15, 2026 |
| FITZGERALD MEGHAN | Director | 5,112 | $0.20 | Sep 15, 2026 |
| Epperly Melissa B, | Director | -600 | $40.38 | Sep 15, 2026 |
| Fitzgerald Meghan | Director | -400 | $40.45 | Sep 15, 2026 |
Explore More Analysis for ROIV
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.